☰

RESOLUTION THERAPEUTICS

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of RESOLUTION THERAPEUTICS's published strategy and is not endorsed by, or produced in cooperation with, RESOLUTION THERAPEUTICS. Company website

Strategic priorities

RESOLUTION THERAPEUTICS operates across 4 stated priorities, with the most concrete near-term plan anchored on clinical advancement.

The EMERALD Phase I/II study represents Resolution's singular focus for clinical validation, with first patient dosed in 2025 and data readout targeted for 2026 to establish safety and efficacy signals for RTX001 in end-stage liver disease patients, driving NAV recovery and determining trajectory toward commercialization.

Active transition from manual, labor-intensive production to automated commercial-scale manufacturing through a £1 million Innovate UK-funded consortium with Cellular Origins and CGT Catapult, integrating autonomous mobile robots, automated sterile welding, and unified digital control to enable "few operators producing many products."

Beyond liver disease, the engineered macrophage platform has demonstrated preclinical potential in GVHD and lung fibrosis, with the £63.5 million Series B specifically funding expansion into new indications, positioning the technology as a multi-asset platform rather than single-indication company.

Challenges we see

  • Operations Manufacturing

    Cell Loss During Manufacturing

    Resolution faces a unique manufacturing challenge where progressive cell loss during macrophage processing threatens yield and commercial viability. Starting material is inherently limited by what can safely be collected from patients with end-stage liver disease.

    Every percentage point of cell recovery is critical; without process optimization, scaling to serve more than 7% of the global eligible patient population remains difficult.

  • Operations Manufacturing

    Manual Batch Scalability

    Current manufacturing relies on manual cleanroom batches involving sterile welds, device setup, and manual transfers performed by highly specialized staff. This fundamentally limits production capacity while driving high cost of goods sold.

    Dependency on specialized operators for routine handling drives a structural cost problem and scalability ceiling that blocks market dominance aspirations.

  • Digital Integration

    Multi-Site Data Fragmentation

    Equipment from multiple vendors including Cytiva, Thermo Fisher Scientific, and Fresenius Kabi generates data in proprietary formats, creating silos between the Edinburgh R&D hub, Stevenage manufacturing facility, and clinical trial sites in Spain and the UK.

    No "Digital Thread" connects operations, preventing end-to-end process understanding and blocking AI/ML initiatives that leadership has publicly advocated for.

  • Compliance Regulatory

    Chain of Identity/Custody Tracking

    Autologous therapy requires 100% accurate tracking of patient cells across multiple sites and processing steps. Current processes involve a mix of digital and paper-based tracking systems that span Edinburgh, Stevenage, and clinical sites.

    Hybrid tracking systems raise the risk of regulatory compliance gaps and errors in patient dosing, threatening both patient safety and BLA/MAA filings.

  • Compliance Regulatory

    Multimodal Potency Assay Complexity

    Unlike single-mechanism therapies, RTX001's multimodal mechanism-of-action spans anti-inflammatory, fibrolytic, and regenerative pathways. Developing potency assays that demonstrate appropriate biological activities under evolving FDA guidance is a significant regulatory hurdle.

    Where draft potency guidance is not fully satisfied, regulatory holds and clinical delays could follow, directly threatening the critical 2026 data readout timeline.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Manufacturing Yield Optimization

    Progressive cell loss during macrophage processing is a critical bottleneck affecting commercial viability. The unique biology of autologous therapy means starting material is inherently limited by patient collection capacity.

    Real-time environmental monitoring and predictive process control can minimize cell attrition and optimize yield per batch, directly addressing the "cell loss paradox" that threatens scalability.

  2. Robotic Platform Enterprise Integration

    The Constellation robotic platform consortium focuses on hardware automation but lacks enterprise integration connecting robotic control layers to Quality Management Systems, ERP, and regulatory reporting engines.

    An Enterprise IT/OT Integration Layer can ensure the platform is "FDA-Ready" from a data integrity perspective, creating the unified digital control layer that records every movement, connection, and process step.

  3. Lab-to-Factory Data Handover

    Edinburgh R&D labs and Stevenage manufacturing hub operate in data silos with fragmented datasets preventing a end-to-end view of the manufacturing process. Technology transfer is hampered by incompatible data formats.

    A unified data fabric aggregating single-cell omics, potency assays, and manufacturing telemetry into a single source of truth would accelerate pipeline expansion and enable AI/ML-driven discovery.

  4. Digital Traceability Compliance

    Chain of Identity and Chain of Custody tracking relies on hybrid digital/paper systems across multiple geographies. This creates audit complexity and increases risk of regulatory non-compliance.

    Electronic Batch Records with 100% digital traceability providing second-by-second compliance records would eliminate human error in patient cell tracking and streamline regulatory submissions.

  5. Potency Assay Data Analytics

    Developing a Potency Assay Matrix for multimodal mechanism-of-action therapy requires correlating multiple biomarkers into actionable insights. Current manual data cleaning and analysis processes cannot keep pace with regulatory timelines.

    AI-enabled analytics pipelines can automate biomarker correlation into a validated Potency Score, simplifying regulatory reporting and accelerating the path to BLA/MAA submission.

What we'd propose

  • Digital CDMO

    CGT Manufacturing IT/OT Integration

    Enterprise integration layer connecting the Constellation robotic manufacturing platform to Quality Management Systems, ERP, and regulatory reporting engines, creating a unified digital control architecture for FDA-ready operations.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Unified Manufacturing Data Platform

    Cloud-based data lake aggregating multi-vendor instrument data, multi-omics research datasets, and manufacturing telemetry into a unified data fabric with standardized schemas enabling AI/ML-ready data streams.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Process Optimization for Cell Yield

    IoT sensor integration and real-time environmental monitoring solution for bioreactor operations, implementing predictive process control to minimize cell attrition and optimize Critical Quality Attributes throughout manufacturing.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    QC Lab Digital Transformation

    Laboratory Execution System implementation connecting analytical instruments to centralized quality systems, automating potency assay data capture and enabling AI-driven biomarker correlation for regulatory submissions.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    Multi-Site Compliance Architecture

    Integrated digital compliance infrastructure spanning Edinburgh R&D, Stevenage manufacturing, and clinical trial sites, ensuring 100% Chain of Identity/Custody integrity with full audit trail capabilities.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what RESOLUTION THERAPEUTICS's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Infrastructure 30 → 85
Fragmented vendor-specific formats with silos between Edinburgh, Stevenage, and clinical sites; no Digital Thread connecting operations
Process Automation 35 → 90
Manual cleanroom batches with consortium robotics in development; 20-month timeline to Constellation platform completion
IT/OT Convergence 25 → 85
Standalone unit operations with no unified digital control layer; ERP/QMS disconnected from manufacturing floor
Analytics & AI 20 → 80
VP Marshall advocacy for ML but proof-of-concept only; data maturity insufficient for production AI deployment
Regulatory Compliance 45 → 95
Hybrid digital/paper tracking creates audit risk; multimodal potency assay complexity under evolving FDA guidance
Cloud & Security 35 → 80
Multi-site connectivity unclear; heightened IP protection requirements given Syncona exit timeline

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with RESOLUTION THERAPEUTICS, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].